Last reviewed · How we verify

L. reuteri Prodentis® lozenges

University of Zagreb · FDA-approved active Small molecule

L. reuteri Prodentis® is a probiotic lozenge containing Lactobacillus reuteri that colonizes the oral cavity and modulates the local oral microbiome to reduce pathogenic bacteria and promote gum health.

L. reuteri Prodentis® is a probiotic lozenge containing Lactobacillus reuteri that colonizes the oral cavity and modulates the local oral microbiome to reduce pathogenic bacteria and promote gum health. Used for Gingivitis and periodontal disease prevention and management, Oral microbiome modulation for gum health.

At a glance

Generic nameL. reuteri Prodentis® lozenges
SponsorUniversity of Zagreb
Drug classProbiotic
ModalitySmall molecule
Therapeutic areaDentistry / Oral Health
PhaseFDA-approved

Mechanism of action

The live L. reuteri bacteria in the lozenge establish themselves in the oral cavity where they produce antimicrobial compounds and compete with pathogenic oral bacteria. This shifts the oral microbiota composition toward a healthier balance, reducing inflammation and supporting periodontal tissue health. The mechanism relies on competitive exclusion and production of bacteriocins rather than a specific molecular target.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: